Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Why the study?
Does aspirin reduce the incidence of cardiovascular disease in primary and secondary prevention populations?
Population
Patients with a history of myocardial infarction, stroke, transient cerebral ischemia, or unstable angina…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Should not change aspirin prescribing in CVD prevention; leaves open efficacy pending large randomized trials.
Structured PICO
Does aspirin reduce the incidence of cardiovascular disease in primary and secondary prevention populations?
P
Population
Patients with a history of myocardial infarction, stroke, transient cerebral ischemia, or unstable angina; patients undergoing acute myocardial infarction; and apparently healthy individuals
I
Intervention
Antiplatelet therapy, particularly aspirin (e.g., 80 mg/day or loading dose of at least 160 mg)
O
Outcome
Incidence of cardiovascular diseasehard clinical
Aspirin is reviewed for its efficacy in primary and secondary prevention of cardiovascular disease, with observational data suggesting a 20% reduction in incidence, though large randomized trials are needed for reliable assessment.
Limitations
- uncontrolled confounding inherent in observational studies
Cite This Study
Hennekens et al. (1989) studied this question.